Pharmaceuticals

Global Menveo Market Expected To Reach $100.16 Billion By 2030 With 5.3% CAGR

May 5, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Menveo Market In 2026 And 2030?

The historical period’s growth can be linked to the broadening of national immunization programs, past occurrences of meningococcal disease outbreaks, improvements in conjugate vaccine technology, a greater understanding of diseases preventable by vaccines, and worldwide vaccination efforts.

Growth in the forecast period can be attributed to escalating investments in vaccine innovation, a heightened focus on preventing outbreaks, the broadening of immunization coverage for adults and adolescents, surging demand for travel-related vaccinations, and the fortification of public health infrastructure. Significant trends anticipated during this period include the increased adoption of conjugate vaccines, a rising emphasis on preventive immunization programs, growing demand for adolescent and travel-related immunizations, the expansion of multivalent vaccine availability, and an enhanced commitment to public health preparedness.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20153&type=smp

What Key Drivers Are Fueling The Growth Of The Menveo Market?

The increasing frequency of meningitis cases is anticipated to drive the expansion of the menveo market in the coming years. Meningitis, an infection, leads to inflammation of the protective membranes that envelop the brain and spinal cord, typically initiated by viral, bacterial, or fungal agents. The escalating incidence of meningitis is primarily influenced by factors such as heightened global movement and compromised immune systems, which elevate the chances of disease transmission. menveo plays a crucial role in public health by offering protection against various strains of Neisseria meningitidis, facilitating early prevention, curtailing disease spread, and diminishing the burden of invasive meningococcal infections. For example, in October 2025, as reported by the UK Health Security Agency, a UK-based government agency, a total of 378 invasive meningococcal disease (IMD) cases were confirmed in 2024–25. Consequently, the rising occurrence of meningitis is fueling the growth of the menveo market.

Menveo Market Driver: Impact Of Global Healthcare Infrastructure Expansion On Market Growth

What Are The Different Segment Types In The Menveo Market Segment Breakdown?

The menveo market covered in this report is segmented –

1) By Type of Vaccine: Conjugate Vaccine, Combination Vaccine

2) By Indication: Meningococcal Disease Prevention, Routine Immunization, Outbreak Control, Travel Vaccination

3) By Age Group: Infants and Young Children, Adolescents, Adults, Older Adults

4) By End User: Hospitals, Vaccination Clinics, Travel Clinics, Academic And Research Institutions, Military And Government Facilities

What Trends Are Shaping The Future Of The Menveo Market?

A significant trend in the menveo market involves the creation of innovative vaccine formulations, such as single-vial, fully liquid preparations, intended to boost convenience, enhance stability, and streamline vaccine administration. Single-vial, fully liquid formulations refer to pharmaceutical products that are pre-mixed and contained in a single vial, with the active ingredients dissolved in a liquid form, ready for immediate use. For instance, in November 2024, GlaxoSmithKline (GSK) plc, a UK-based pharmaceutical industry company, secured approval from the European Commission (EC) for a new presentation of its meningococcal vaccine, Menveo, for active immunization against invasive meningococcal disease (IMD) caused by serogroups A, C, W, and Y. The vaccine is now licensed for use in children aged two years and older, adolescents, and adults. Key features of the vaccine’s approval include its authorization for active immunization in the European Union for children from two years of age, adolescents, and adults, with a new single-vial, fully liquid presentation that removes the requirement for reconstitution before use.

Who Are The Well-Known Companies In The Menveo Market?

Major companies operating in the menveo market are GlaxoSmithKline (GSK) Plc

Get The Full Menveo Market Report:

https://www.thebusinessresearchcompany.com/report/menveo-global-market-report

Which Region Leads The Menveo Market In Overall Market Size?

North America was the largest region in the menveo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the menveo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Menveo Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/menveo-global-market-report

Browse Through More Reports Similar to the Global Menveo Market 2026, By The Business Research Company

Renewable Diesel Market Report 2026

https://www.thebusinessresearchcompany.com/report/renewable-diesel-global-market-report

Hypermarkets Market Report 2026

https://www.thebusinessresearchcompany.com/report/hypermarkets-global-market-report

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795